Patents Assigned to ONO
  • Publication number: 20130184236
    Abstract: Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 18, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: ONO PHARMACEUTICAL CO., LTD.
  • Patent number: 8476293
    Abstract: The present invention relates to the compound represented by formula (I): (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: July 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Yoshifumi Kagamiishi, Junichiro Manako
  • Patent number: 8476266
    Abstract: A compound represented by formula (I), wherein R1 represents a hydrogen atom, etc., R2 and R3 each independently represents a hydrogen atom, optionally oxidized C1-4 alkyl group or optionally protected hydroxyl group, or R2 and R3 taken together represent optionally oxidized C2-5 alkylene group, R4 represents an optionally oxidized C1-6 alkyl group, etc., R5 represents an optionally oxidized C1-6 alkyl group, etc., R6 represents an optionally oxidized C1-6 alkyl group, etc., m represents 0 or an integer from 1 to 3, n represents 0 or an integer from 1 to 4, and i represents 0 or an integer from 1 to 7.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: July 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Atsushi Naganawa, Toshihiko Nagase
  • Patent number: 8476290
    Abstract: A compound represented by formula (I): a salt thereof, an N-oxide thereof, or a solvate thereof (symbols in the formula are as described in the specification). The compounds of the present invention exhibit very low risk of side effects and also have persistent and strong antagonistic activity against CXCR4, and are therefore useful as pharmaceuticals, for example, as a preventive and/or therapeutic agent for inflammatory and immune diseases, infections (for example, HIV infection), diseases associated with HIV infection (for example, acquired immunodeficiency syndrome (AIDS)), cancer, cancer metastasis, psychoneurotic diseases and cardiovascular diseases (for example, retinopathy), metabolic diseases, cancerous diseases, or as an agent for regeneration therapy.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: July 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Koji Yoshida, Hiroshi Ochiai, Kousuke Tani, Shiro Shibayama, Miki Kasano
  • Publication number: 20130164294
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 27, 2013
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 8460886
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: June 11, 2013
    Assignees: Ono Pharmaceutical Co., Ltd., Medarex, Inc.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai
  • Publication number: 20130143934
    Abstract: An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system.
    Type: Application
    Filed: January 25, 2013
    Publication date: June 6, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: ONO PHARMACEUTICAL CO., LTD.
  • Publication number: 20130133091
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: August 15, 2011
    Publication date: May 23, 2013
    Applicants: Ono Pharmaceutical Co., LTD., Medarex, Inc.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Sellby, Bing Chen, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20130116700
    Abstract: Provided are: a screw guide template, screw guide template system, and drilling method whereby a hole can be drilled in an accurate position of a member to be drilled, in an accurate direction; and a spinal fixation method whereby a spinal fixation screw can be inserted into an accurate position in an accurate direction. The screw guide template (20) comprises: a close-contact face (21) to be closely contacted to the member; and a through hole (22) having one opening (23a) on the close-contact face; the close-contact face has a shape in male-female relation with a surface shape (31) of the member including a portion (32) to be drilled; and when the close-contact face is closely contacted to the portion to be drilled, the opening and portion to be drilled overlap each other so that the through hole is coaxial with the hole to be drilled by the drilling means.
    Type: Application
    Filed: May 30, 2011
    Publication date: May 9, 2013
    Applicants: ONO&CO., LTD., AKITA UNIVERSITY
    Inventors: Taku Sugawara, Kazuo Mizoi, Naoki Higashiyama, Hidenori Ono, Hisayuki Sugiyama
  • Patent number: 8435953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 7, 2013
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • Patent number: 8436026
    Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: May 7, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
  • Publication number: 20130109699
    Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.
    Type: Application
    Filed: July 5, 2011
    Publication date: May 2, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
  • Patent number: 8433546
    Abstract: A response surface model is created without a drawback of creating a linear model that does not approximate to samples belonging to a partitioned region. Provided are: an input unit 1 that inputs samples composed of factor values and a response value; a sample placement unit 21 that places the samples in spaces, the samples being input by way of the input unit 1; a linear modeling unit 230 that creates the linear model for each region, based on coordinate values of the samples belonging to the region; a region partition unit 22 that partitions the linear model, based on the samples belonging to the region; a partition region determination unit 221 that determines whether it is possible to partition the region, based on the samples belonging to the region to be partitioned; and a modeling unit 23 that creates a response surface model by placing each linear model in the spaces when the partition region determination unit 221 has determined that partition is impossible in all the regions.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: April 30, 2013
    Assignee: Ono Sokki Co., Ltd.
    Inventors: Yoshihiro Hashimoto, Masami Omori, Michlo Murase
  • Patent number: 8420810
    Abstract: A compound of a formula (I): wherein R1 represents a C3-10 branched alkyl group which may be substituted; R2 represents a hydrogen atom or a C1-4 alkyl group which may be substituted; R3 represents a C1-4 alkyl group which may be substituted or a halogen atom; R4 represents a C1-4 alkyl group which may be substituted; and ring 1 represents a cyclic group which has planarity and may have a substituent group, a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a medicinal component having CRF antagonistic activity for the prevention and/or treatment of a neuropsychiatric disease, a peripheral organ disease and the like.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: April 16, 2013
    Assignee: Ono Pharmaceutical, Co., Ltd.
    Inventors: Tetsuji Saito, Tetsuo Obitsu, Yoshifumi Kagamiishi
  • Publication number: 20130090482
    Abstract: The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.
    Type: Application
    Filed: June 20, 2011
    Publication date: April 11, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Junya Ueda, Shizuka Ono, Takahiro Nekado, Manabu Fujita
  • Publication number: 20130085275
    Abstract: A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.
    Type: Application
    Filed: November 21, 2012
    Publication date: April 4, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: ONO PHARMACEUTICAL CO., LTD.
  • Patent number: 8410276
    Abstract: A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: April 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Yoshikazu Takaoka, Shiro Shibayama, Rena Nishizawa
  • Patent number: 8410171
    Abstract: An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: April 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Akio Nishiura, Hikaru Sugihara, Kazuya Abe
  • Patent number: 8410281
    Abstract: Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: April 2, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Akihiro Kinoshita, Hidekazu Matsuya, Hiroki Okada
  • Patent number: 8404858
    Abstract: An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: March 26, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Akihiro Kinoshita, Hidekazu Matsuya